Michelle Basil compensation by year
HAEMONETICS Summary Compensation Table · all 9 fiscal years held| Component | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|
| Salary | $425,818 | $440,811 | $461,803 | $474,204 | $477,619 | $498,576 | $517,194 | $537,870 | $558,776 |
| Bonus | $150,000 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $822,699 | $862,844 | $1,298,603 | $1,019,211 | $2,241,162 | $1,382,412 | $1,458,507 | $1,471,617 | $1,749,291 |
| Option awards | $249,999 | $249,997 | $274,990 | $299,996 | $349,982 | $349,998 | $374,975 | $399,999 | $474,983 |
| Non-equity incentive | $411,321 | $578,807 | $489,838 | $325,364 | $293,193 | $740,411 | $694,550 | $356,242 | $599,766 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $22,371 | $16,387 | $17,209 | $16,137 | $17,778 | $19,005 | $26,177 | $28,715 | $26,727 |
| Total | $2,082,208 | $2,148,846 | $2,542,443 | $2,134,912 | $3,379,734 | $2,990,402 | $3,071,403 | $2,794,443 | $3,409,543 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: HAEMONETICS CORP DEF 14A filed June 9, 2026, accession 0000313143-26-000074, and prior-year filings.
How this page was built: the HAEMONETICS CORP filed document, accession 0000313143-26-000074. Every figure is read from that document and cited to the page and table it appears in. Filed June 9, 2026.
Equity holdings
unvested awards at FY2026 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 13,510 | $730,080 | — |
| PSU | 8,411 | $454,530 | — |
| PSU | 8,356 | $451,558 | — |
| RSU | 6,755 | $365,040 | — |
| RSU | 2,786 | $150,555 | — |
| RSU | 1,519 | $82,087 | — |
| RSU | 1,402 | $75,764 | — |
| Option | 14,626 | — | $70.31 |
| Option | 3,552 | — | $57.60 |
| Option | 4,751 | — | $89.16 |
| Option | 6,888 | — | $95.73 |
Per the Outstanding Equity Awards at Fiscal Year-End table in HAEMONETICS CORP's FY2026 proxy; value at the fiscal year-end close, as the company printed it.
HAEMONETICS’s named executive officers, FY2026
as the company reported each| Named executive officer | Role | FY2026 total |
|---|---|---|
| Christopher Simon | President and Chief Executive Officer | $12,044,701 |
| James D'Arecca | Executive Vice President, Chief Financial Officer | $3,623,016 |
| Michelle Basil · this page | Executive Vice President, General Counsel | $3,409,543 |
| Frank Chan | Executive Vice President, Chief Operating Officer | $3,336,849 |
| Roy Galvin | Executive Vice President, Chief Commercial Officer | $3,039,118 |
Michelle Basil's compensation dossier, HAEMONETICS
You have read Michelle Basil's totals and holdings. The dossier adds each equity grant HAEMONETICS disclosed for Michelle Basil and HAEMONETICS's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full HAEMONETICS compensation record
free company briefThis page is one person within HAEMONETICS's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the HAEMONETICS proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order HAEMONETICS's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are HAEMONETICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.